If so, interventions targeting specific LAT1—such as JPH203, a LAT1 inhibitor that has recently shown to be tolerated in patients with advanced solid tumors [57]—could be administered using precision medicine approaches in patients with breast cancer and potentially other tumors. Here, LAT is linked to breast cancer.